3 most recent filings and news items mentioning KYMR. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/KYMR/news?limit=20"
Pull KYMR filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayKymera Therapeutics reported enrollment for the KT-621 AD trial completed ahead of schedule and completed the quarter with $1.5 billion in cash, extending runway through 2029. The advancement is meaningful for the pipeline but has limited immediate impact on current market value.
View filing at SEC.gov →Kymera Therapeutics appointed immunology leader Dr. Terence Rooney as Chief Medical Officer to lead clinical development, succeeding Dr. Jared Gollob, who is retiring.
View filing at SEC.gov →Kymera finished enrollment early for the Phase 2b BROADEN2 trial for atopic dermatitis candidate KT-621, accelerating data timelines to year-end 2026. The early success supports the company's plan to initiate Phase 3 trials in mid-2027 following regulatory review.
View filing at SEC.gov →